Skip to content

Study · Observational study · n = 549 · 2009

5 results

Reduced daily risk of glycemic variability: comparison of exenatide with insulin glargine.

McCall AL, Cox DJ, Brodows R, Crean J, Johns D, Kovatchev B

Diabetes technology & therapeutics1 Jun 2009Cited by 36 (Europe PMC)

PMID19459761 (opens in a new tab)PMCIDPMC2768873 (opens in a new tab)DOI10.1089/dia.2008.0107 (opens in a new tab)PepBankPUB-19459761
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, exenatide was linked to a lower average daily risk range than insulin glargine.

    In plain wordsIn patients with diabetes, exenatide was linked to lower daily glucose risk than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseAverage daily risk range
    Study

    n = 549

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    ADRR
    16.33 index
    exenatide
    ADRR
    18.54 index
    insulin glargine

    Source sentences

    Summary
    Exenatide treatment reduced ADRR overall (exenatide, mean +/- SEM, 16.33 +/- 0.45; insulin glargine, 18.54 +/- 0.49; P = 0.001).
    2 context sentences
    Summary · context
    New (LBGI, HBGI, and ADRR) and conventional variability analyses were applied retrospectively to SMBG data from patients with type 2 diabetes suboptimally controlled with metformin and a sulfonylurea plus exenatide or insulin glargine as a next therapeutic step.
    Summary · context
    Exenatide- (n = 282) and insulin glargine-treated (n = 267) patients were well matched.
  2. 02HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, exenatide was linked to more patients having low glucose variability risk than insulin glargine.

    In plain wordsIn patients with diabetes, exenatide was linked to more patients having low glucose variability risk than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    IncreaseLow risk for glucose variability
    Study

    n = 549

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Measurements

    Low-risk patients
    77%
    exenatide
    Low-risk patients
    62%
    insulin glargine

    Source sentences

    Summary
    Seventy-seven percent of exenatide-treated patients were at low risk for glucose variability compared with 62% of glargine-treated patients (P = 0.00023).
    2 context sentences
    Summary · context
    New (LBGI, HBGI, and ADRR) and conventional variability analyses were applied retrospectively to SMBG data from patients with type 2 diabetes suboptimally controlled with metformin and a sulfonylurea plus exenatide or insulin glargine as a next therapeutic step.
    Summary · context
    Exenatide- (n = 282) and insulin glargine-treated (n = 267) patients were well matched.
  3. 03HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, exenatide was linked to a lower low blood glucose index than insulin glargine across comparisons.

    In plain wordsIn patients with diabetes, exenatide was linked to a lower low blood glucose index than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseLow blood glucose index
    Study

    n = 549

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LBGI for exenatide remained minimal for all categories and significantly lower than glargine for all comparisons, and HBGI for exenatide remained low or moderate for all categories and significantly lower than glargine after the morning and evening meals.
    2 context sentences
    Summary · context
    New (LBGI, HBGI, and ADRR) and conventional variability analyses were applied retrospectively to SMBG data from patients with type 2 diabetes suboptimally controlled with metformin and a sulfonylurea plus exenatide or insulin glargine as a next therapeutic step.
    Summary · context
    Exenatide- (n = 282) and insulin glargine-treated (n = 267) patients were well matched.
  4. 04HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, exenatide was linked to a lower high blood glucose index than glargine after morning and evening meals.

    In plain wordsIn patients with diabetes, exenatide was linked to a lower high glucose index than glargine after morning and evening meals.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseHigh blood glucose index
    Study

    n = 549

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    LBGI for exenatide remained minimal for all categories and significantly lower than glargine for all comparisons, and HBGI for exenatide remained low or moderate for all categories and significantly lower than glargine after the morning and evening meals.
    2 context sentences
    Summary · context
    New (LBGI, HBGI, and ADRR) and conventional variability analyses were applied retrospectively to SMBG data from patients with type 2 diabetes suboptimally controlled with metformin and a sulfonylurea plus exenatide or insulin glargine as a next therapeutic step.
    Summary · context
    Exenatide- (n = 282) and insulin glargine-treated (n = 267) patients were well matched.
  5. 05HumanObservational studyEfficacy outcome

    In patients with type 2 diabetes, conventional analyses linked exenatide to lower glucose variability than insulin glargine.

    In plain wordsIn patients with diabetes, conventional analyses linked exenatide to lower glucose variability than insulin glargine.

    Peptide
    Exenatide (exendin-4)
    Outcome
    DecreaseConventional glucose variability
    Study

    n = 549

    Comparator
    Insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Reduced variability in exenatide-treated patients was shown by conventional methods but provided no indications of risk.
    2 context sentences
    Summary · context
    New (LBGI, HBGI, and ADRR) and conventional variability analyses were applied retrospectively to SMBG data from patients with type 2 diabetes suboptimally controlled with metformin and a sulfonylurea plus exenatide or insulin glargine as a next therapeutic step.
    Summary · context
    Exenatide- (n = 282) and insulin glargine-treated (n = 267) patients were well matched.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.